Cargando…

Tixagevimab and cilgavimab for COVID-19 prophylaxis

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	NPS MedicineWise 2022
Materias:	New Drugs
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584788/ https://www.ncbi.nlm.nih.gov/pubmed/36382164 http://dx.doi.org/10.18773/austprescr.2022.058

Ejemplares similares

Tixagevimab + Cilgavimab: First Approval
por: Keam, Susan J.
Publicado: (2022)

Safety and immunogenicity of cilgavimab-tixagevimab for COVID-19 pre-exposure prophylaxis in immunocompromised patients
por: Fernández-Prada, María, et al.
Publicado: (2023)

Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi
por: Zamprogna, Giulia, et al.
Publicado: (2023)

Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab–cilgavimab
por: Solera, Javier T, et al.
Publicado: (2023)

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
por: Levin, Myron J., et al.
Publicado: (2022)

A case of prolonged COVID‐19 treated with tixagevimab/cilgavimab
por: Shimizu, Takahiro, et al.
Publicado: (2023)

Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients
por: Nguyen, Yann, et al.
Publicado: (2022)

P57 PRE-EXPOSURE PROPHYLAXIS FOR COVID-19 WITH TIXAGEVIMAB/CILGAVIMAB (EVUSHELD) IN PATIENTS WITH MULTIPLE MYELOMA
por: Ntanasis-Stathopoulos, I., et al.
Publicado: (2023)

Tixagevimab/ Cilgavimab Outcomes Among Patients with Immunodeficiency
por: Sullivan, Juliana
Publicado: (2023)

AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019
por: Levin, Myron J, et al.
Publicado: (2022)

COVID-19 morbidity decreases with tixagevimab–cilgavimab preexposure prophylaxis in kidney transplant recipient nonresponders or low-vaccine responders
por: Kaminski, Hannah, et al.
Publicado: (2022)

A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment
por: Focosi, Daniele, et al.
Publicado: (2022)

Efficacy and Safety of Tixagevimab/Cilgavimab to Prevent COVID-19 (Pre-Exposure Prophylaxis): A Systematic Review and Meta-Analysis
por: Alhumaid, Saad, et al.
Publicado: (2022)

Tixagevimab and Cilgavimab (Evusheld™) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study
por: Jakimovski, Dejan, et al.
Publicado: (2023)

Pre-exposure Prophylaxis with Tixagevimab-cilgavimab did not Reduce Severity of COVID-19 in Lung Transplant Recipients with Breakthrough Infection
por: Sindu, Devika, et al.
Publicado: (2023)

Letermovir for cytomegalovirus prophylaxis
Publicado: (2019)

Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience
por: Akinosoglou, Karolina, et al.
Publicado: (2022)

Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies
por: Angotzi, Francesco, et al.
Publicado: (2023)

Neutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipients
por: Karaba, Andrew H., et al.
Publicado: (2023)

EE572 Cost-Effectiveness of AZD7442 (Tixagevimab and Cilgavimab) for Pre-exposure Prophylaxis Against COVID-19 in the Immunocompromised Population
por: Sutton, K, et al.
Publicado: (2022)

Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2023)

Cilgavimab/Tixagevimab as alternative therapeutic approach for BA.2 infections
por: Dichtl, Stefanie, et al.
Publicado: (2022)

Real world effectiveness of tixagevimab/cilgavimab (Evusheld) in the Omicron era
por: Chen, Benjamin, et al.
Publicado: (2023)

INCIDENCE OF COVID-19 INFECTIONS IN ADULTS WITH PRIMARY IMMUNODEFICIENCY AFTER RECEIVING TIXAGEVIMAB AND CILGAVIMAB
por: Johnson, S., et al.
Publicado: (2022)

498. Covid-19 Hospitalization Rates in Kidney Transplant Patients Treated with Tixagevimab/Cilgavimab
por: Dugan, Katherine, et al.
Publicado: (2023)

Safety and efficacy of pre-exposure prophylaxis with tixagevimab/cilgavimab (Evusheld) in patients with glomerular diseases who received rituximab
por: Sciascia, Savino, et al.
Publicado: (2023)

Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis
por: Ordaya, Eloy E., et al.
Publicado: (2023)

Tixagevimab and Cilgavimab (Evusheld) as Pre-exposure Prophylaxis for COVID-19 in Patients With Inflammatory Bowel Disease: A Propensity Matched Cohort Study
por: Desai, Aakash, et al.
Publicado: (2023)

Real-World Effectiveness of Tixagevimab and Cilgavimab (Evusheld) in Patients With Hematological Malignancies
por: Ocon, Anthony J., et al.
Publicado: (2022)

LB5. PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults
por: Levin, Myron J, et al.
Publicado: (2021)

Incidence of breakthrough COVID-19 in patients with hematological disorders who received pre-exposure prophylaxis with tixagevimab-cilgavimab: a retrospective study in Japan
por: Haraguchi, Mizuki, et al.
Publicado: (2023)

1353. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of COVID-19: Final Analysis of the STORM CHASER Phase 3 Study
por: Levin, Myron J, et al.
Publicado: (2023)

Tixagevimab and Cilgavimab (Evusheld – AstraZeneca) efficacy in preventing COVID infection in immunocompromised patients
por: Miot, Christelle, et al.
Publicado: (2023)

(653) Tixagevimab and Cilgavimab Reduced the Likelihood of Covid after Heart Transplant in the Age of Omicron
por: Lee, R., et al.
Publicado: (2023)

The effect of tixagevimab-cilgavimab on clinical outcomes in patients with COVID-19: A systematic review with meta-analysis
por: Wang, Yong, et al.
Publicado: (2023)

‘Real-World’ Impact of Tixagevimab/Cilgavimab (Evusheld) on COVID-19 Outcomes in Patients Undergoing Cellular Therapies
por: Sannareddy, Aishwarya, et al.
Publicado: (2023)

Tixagevimab and Cilgavimab (Evusheld) in Rituximab-treated Antineutrophil Cytoplasmic Antibody Vasculitis Patients
por: Aqeel, Faten, et al.
Publicado: (2022)

Cardiac and vascular serious adverse events following tixagevimab–cilgavimab – Author's reply
por: Maselkar, Sheetal, et al.
Publicado: (2023)

P1574: EFFICACY AND SAFETY OF TIXAGEVIMAB AND CILGAVIMAB (EVUSHELD) IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
por: Aleshina (Gavrilina), Olga, et al.
Publicado: (2023)

1339. Effects of Tixagevimab-Cilgavimab in Clinical Practice is Consistent with Preliminary Neutralization Studies
por: Dluzynski, Daniela, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_al2291fv3blvkn1hui9cpfrv3a